Skip to main content
. 2020 Sep 29;19:155. doi: 10.1186/s12933-020-01121-5

Table 1.

Baseline characteristics of the study population by quintiles of TyG-index: Tehran Lipid and Glucose Study

Variables TyG-index quartiles P-value Total (n = 7521)
1 (< 8.4) 2 (8.4–8.7) 3 (8.7–9.0) 4 (9.0–9.4) 5 (≥ 9.4)
(n = 1503) (n = 1506) (n = 1504) (n = 1504) (n = 1504)
Age (years) 43.1 ± 12.3 45.5 ± 12.2 47.1 ± 12.0 47.3 ± 11.7 50.3 ± 11.4 < 0.001 46.6 ± 12.1
Gender
 Male 588 (39.1) 664 (44.1) 696 (46.3) 696 (46.3) 723 (48.1) < 0.001 3367 (44.8)
 Female 915 (60.9) 842 (55.9) 808 (53.7) 808 (53.7) 781 (51.9) 4154 (55.2)
WC (cm) 83.2 ± 10.7 88.3 ± 10.9 91.7 ± 10.3 94.0 ± 10.6 96.5 ± 10.2 < 0.001 90.7 ± 11.5
BMI (kg/m2) 25.1 ± 4.27 26.8 ± 4.39 27.9 ± 4.40 28.7 ± 4.32 29.1 ± 4.32 < 0.001 27.5 ± 4.57
Education (years)
 < 6 451 (30.0) 560 (37.2) 604 (40.2) 639 (42.5) 789 (52.5) < 0.001 3043 (40.5)
 6–12 834 (55.5) 749 (49.7) 708 (47.1) 698 (46.4) 559 (37.2) 3548 (47.2)
 ≥ 12 218 (14.5) 197 (13.1) 192 (12.8) 167 (11.1) 156 (10.4) 930 (12.4)
Smoking
 Never 1164 (77.4) 1118 (74.2) 1134 (75.4) 1118 (74.3) 1101 (73.2) 0.075 5635 (74.9)
 Past 104 (6.9) 114 (7.6) 122 (8.1) 140 (9.3) 142 (9.4) 622 (8.3)
 Current 235 (15.6) 274 (18.2) 248 (16.5) 246 (16.4) 261 (17.4) 1264 (16.8)
Low physical activity 1002 (66.7) 996 (66.1) 1066 (70.9) 1056 (70.2) 1071 (71.2) 0.002 5191 (69.0)
FH-CVD 227 (15.1) 239(15.9) 239 (15.9) 253 (16.8) 264 (17.6) 0.407 1222 (16.2)
T2D 16 (1.1) 54 (3.6) 78 (5.2) 195 (13.0) 645 (42.9) < 0.001 988 (13.1)
Hypertension 162 (10.8) 281 (18.7) 375 (24.9) 464 (30.9) 577 (38.4) < 0.001 1859 (24.7)
Lipid Lowering drugs 6 (0.4) 18 (1.2) 41 (2.7) 54 (3.6) 154 (10.2) < 0.001 273 (3.6)
LDL-C (mmol/L) 2.98 ± 0.76 3.40 ± 0.81 3.61 ± 0.83 3.76 ± 0.92 3.91 ± 1.06 < 0.001 3.53 ± 0.94
HDL-C (mmol/L) 1.23 ± 0.29 1.13 ± 0.29 1.05 ± 0.26 1.01 ± 0.24 0.95 ± 0.25 < 0.001 1.07 ± 0.28

Data are represented as mean ± SD or frequency (percent)

TyG-index triglyceride and glucose index, WC waist circumference, BMI body mass index, FH-CVD family history of cardiovascular disease, T2D type 2 diabetes, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol